There are different BCR-ABL1 fusion genes that are translated into proteins that are different
from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute …

Chronic myeloid leukemia is driven by a hybrid gene, BCR-ABL1, that codes for a
leukemogenic tyrosine kinase (TK) protein of 210 KDa (p210 BCR-ABL1). Resistance to TK …

Fusion genes are a major cause of cancer. Their rapid and accurate diagnosis can inform
clinical action, but current molecular diagnostic assays are restricted in resolution and …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …

With treatment-free remission (TFR) rapidly becoming the ultimate goal of therapy in chronic
myeloid leukemia (CML), there is a need to develop strategies to maximize sustained TFR …

The introduction of tyrosine kinase inhibitors (TKIs) has changed the treatment paradigm of
chronic myeloid leukemia (CML), leading to a dramatic improvement of the outcome of CML …

Chronic myeloid leukemia (CML) is characterized by the presence of the BCR-ABL1 fusion
gene. In more than 95% of CML patients, the typical BCR-ABL1 transcript subtypes are …

Several studies have compared the molecular responses between e14a2 and e13a2 BCR::
ABL1 transcripts in chronic myeloid leukemia (CML) patients treated with front‐line imatinib …

Simple Summary Chronic myeloid leukemia (CML) is a blood cancer currently well
managed with drugs that inhibit the protein responsible for the disease. However, some …

Abstract Background Chronic Myeloid Leukemia (CML) is characterized by the
overproduction of BCR-ABL, a tyrosine kinase with constitutive activity, in which the majority …